Nivolumab plus ipilimumab in non-small-cell lung cancer

被引：43
|
作者：
Reck, Martin [1 ]
Borghaei, Hossein [2 ]
O'Byrne, Kenneth J. [3 ,4 ]
机构：
[1] German Ctr Lung Res, Airway Res Ctr North, LungenClin Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
[2] Fox Chase Canc Ctr, Dept Hematol Oncol, Div Thorac Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA
[3] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld 4102, Australia
[4] Queensland Univ Technol, Brisbane, Qld 4102, Australia
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 19期
关键词：
atezolizumab; CTLA-4; immunotherapy; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; PD-1; PD-L1; tumor mutational burden; TUMOR MUTATIONAL BURDEN; OPEN-LABEL; PHASE-III; ANTI-PD-1; ANTIBODY; 1ST-LINE TREATMENT; STAGE IV; MAINTENANCE BEVACIZUMAB; CTLA-4; BLOCKADE; SOLID TUMORS; DOCETAXEL;
D O I：
10.2217/fon-2019-0031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single agents and in combination. In this Review, we examine the potential role of dual immune checkpoint inhibition with nivolumab plus ipilimumab in the management of patients with previously untreated advanced non-small-cell lung cancer, based on results from the Phase III CheckMate 227 study. Immunotherapies with indications in the first-line treatment of non-small-cell lung cancer include pembrolizumab alone and combined with chemotherapy, and atezolizumab combined with bevacizumab and chemotherapy. CheckMate 227 is the first Phase III study evaluating first-line chemotherapy-sparing combination immunotherapy and including tumor mutational burden as a biomarker for patient selection.
引用
收藏
页码：2287 / 2302
页数：16
相关论文
共 50 条
  • [1] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [2] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer Reply
    Hellmann, Matthew D.
    Ramalingam, Suresh S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 875 - 875
  • [3] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2020 - 2031
  • [4] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
    Wan, Xiaomin
    Zeng, Xiaohui
    Peng, Liubao
    Peng, Ye
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Deng, Qijian
    Tan, Chongqing
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
    Nishimura, Tomoka
    Ninomiya, Kiichiro
    Nakashima, Mitsutaka
    Akagi, Satoshi
    Kuribayashi, Tadahiro
    Higo, Hisao
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Ito, Hiroshi
    Kiura, Katsuyuki
    [J]. INTERNAL MEDICINE, 2023, 62 (09) : 1319 - 1322
  • [6] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
    Reuss, Joshua E.
    Anagnostou, Valsamo
    Cottrell, Tricia R.
    Smith, Kellie N.
    Verde, Franco
    Zahurak, Marianna
    Lanis, Mara
    Murray, Joseph C.
    Chan, Hok Yee
    McCarthy, Caroline
    Wang, Daphne
    White, James R.
    Yang, Stephen
    Battafarano, Richard
    Broderick, Stephen
    Bush, Errol
    Brock, Malcolm
    Ha, Jinny
    Jones, David
    Merghoub, Taha
    Taube, Janis
    Velculescu, Victor E.
    Rosner, Gary
    Illei, Peter
    Pardoll, Drew M.
    Topalian, Suzanne
    Naidoo, Jarushka
    Levy, Ben
    Hellmann, Matthew
    Brahmer, Julie R.
    Chaft, Jamie E.
    Forde, Patrick M.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [7] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (05): : 492 - 492
  • [9] Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
    Feldman, Hope
    Sepesi, Boris
    Leung, Cheuk H.
    Lin, Heather
    Weissferdt, Annikka
    Pataer, Apar
    William Jr, William N.
    Walsh, Garrett L.
    Rice, David C.
    Roth, Jack A.
    Mehran, Reza J.
    Hofstetter, Wayne L.
    Antonoff, Mara B.
    Rajaram, Ravi
    Gibbons, Don L.
    Lee, J. Jack
    Heymach, John V.
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Cascone, Tina
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04):
  • [10] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345